차세대 시퀀싱 시장 : 제공별, 유형별, 기술별, 워크플로우별, 최종사용자별, 용도별, 지역별 - 세계 예측(-2030년)

The next-generation sequencing market is expected to reach USD 29.53 billion in 2030, up from USD 14.94 billion in 2025, at a CAGR of 14.6% during the forecast period.

The growing application of NGS in oncology, infectious diseases, reproductive health, metagenomics, and personalized medicine is the primary driver of market expansion. Meanwhile, advanced bioinformatics tools for data analysis and interpretation are facilitating the use of NGS, thereby helping a wider user base adopt the technique.

"Consumables accounted for the largest share of the product segment in the NGS market in 2024."

The NGS products market is segmented into consumables, platforms, and bioinformatics tools. In 2024, consumables held the largest share. This segment includes reagents, library preparation kits, sequencing flow cells, and sample preparation kits, which are used in high volumes across many applications. Demand remains robust because consumables are purchased repeatedly, unlike instruments, which are generally one-time investments. The growing use of targeted sequencing and custom panels is also driving demand for specialized, application-specific consumables. Furthermore, an expanding user base and ongoing improvements in sequencing chemistries are drawing more customers toward consumables to simplify their workflows and improve data quality.

"The academic & research institutes segment accounted for the largest share by services end-user segment in the next-generation sequencing market in 2024."

The next-generation sequencing services market is segmented by end user into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinical laboratories, and other users. In 2024, academic and research institutes held the largest share. This leadership is supported by strong government and private funding for research programs, enabling higher spending on NGS-related needs, including instruments and consumables. Pharmaceutical and biotechnology companies represented the second-largest end-user segment in the market.

"The Asia Pacific region will grow at the highest CAGR from 2025 to 2030."

The Asia Pacific region is estimated to be the fastest-growing segment of the market, owing to large-scale population genomics projects and rising demand for precision medicines. Additionally, the rising prevalence of rare and genetic diseases is attributed to the aging populations in countries such as Japan and China. These factors are supporting the adoption of sequencing technologies in healthcare management and treatment, driving market growth.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45% CXOs and Director-level - 30%, and Executives - 25%,
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, and Middle East -5%.

List of Companies Profiled in the Report:

• Illumina, Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Danaher Corporation (US)
• QIAGEN (Netherlands)
• Agilent Technologies, Inc. (US)
• Revvity (US)
• Eurofins Scientific (Luxembourg)
• PacBio (US)
• Oxford Nanopore Technologies plc. (UK)
• Takara Bio Inc. (Japan)
• BGI Group (China)
• Merck KGaA (Germany)
• BD (US)
• 10X Genomics (US)
• New England Biolabs (US)
• Promega Corporation (US)
• Novogene Co., Ltd. (China)
• LGC Limited (UK)
• WuXi Biologics (China)
• MGI Tech Co. Ltd. (China)
• Tecan Trading AG (Switzerland)
• Twist Biosciences (US)
• Azenta US, Inc. (US)
• GenScript (US)
• SD Biosensor, Inc. (South Korea)
• Fulgent Genetics (US)
• Hamilton Company (US)
• Zymo Research Corporation (US)
• NeoGenomics Laboratories (US)
• Psomagen (US)

Research Coverage:

The scope of the report covers detailed information on the major factors, such as drivers, challenges, opportunities, and restraints, that influence the growth of the NGS market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, product and service portfolio, key strategies such as product and service launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the NGS market. Competitive analysis of top players and upcoming startups in the NGS market ecosystem is also covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall NGS market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to better position their business and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following points:

Analysis of key drivers (advancements in sequencing platforms, rising clinical applications of sequencing, growing demand for precision medicine, declining sequencing costs), restraints (complex data analysis, high initial capital investment), opportunities (integration of AI and ML, adoption of long-read sequencing technologies, emphasis on multiomics integration), and challenges (standardization issues) influencing the growth of the market.

• Product Development/Innovation: Detailed insights on newly launched products/services of the next-generation sequencing market
• Market Development: Comprehensive information about lucrative markets - the report analyzes the market across varied regions
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the next-generation sequencing market
• Competitive Assessment: Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), QIAGEN (Netherlands), Agilent Technologies, Inc. (US), Revvity (US), Eurofins Scientific (Luxembourg), PacBio (US), Oxford Nanopore Technologies plc. (UK), Takara Bio Inc. (Japan), BGI Group (China), Merck KGaA (Germany), BD (US), 10X Genomics (US), New England Biolabs (US), Promega Corporation (US), Novogene Co., Ltd. (China), LGC Limited (UK), WuXi Biologics (China), MGI Tech Co. Ltd. (China), Tecan Trading AG (Switzerland), Twist Biosciences (US), Azenta US, Inc. (US), GenScript (US), SD Biosensor, Inc. (South Korea), Fulgent Genetics (US), Hamilton Company (US), Zymo Research Corporation (US), NeoGenomics Laboratories (US), and Psomagen (US)

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
• 1.4 YEARS CONSIDERED
• 1.5 CURRENCY CONSIDERED
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN NEXT-GENERATION SEQUENCING MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 NEXT-GENERATION SEQUENCING MARKET OVERVIEW
• 3.2 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY OFFERING AND COUNTRY
• 3.3 NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY
• 3.4 NEXT-GENERATION SEQUENCING MARKET, BY OFFERING, 2026 VS. 2031 (%)

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Advancements in sequencing platforms
    • 4.2.1.2 Rising clinical applications of sequencing
    • 4.2.1.3 Growing demand for precision medicine
    • 4.2.1.4 Declining costs of sequencing
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Data analysis complexity
    • 4.2.2.2 High capital investments and expenses
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Integration of AI and ML
    • 4.2.3.2 Adoption of long-read sequencing technologies
    • 4.2.3.3 Emphasis on multiomics integration
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Standardization issues
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVIES BY TIER 1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 THREAT FROM SUBSTITUTES
  • 5.1.5 THREAT FROM NEW ENTRANTS
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY
  • 5.2.4 R&D TRENDS IN GLOBAL BIOTECH INDUSTRY
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
  • 5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER
    • 5.5.1.1 Average selling price trend of platforms, by key player
    • 5.5.1.2 Average selling price trend of consumables, by key player
  • 5.5.2 AVERAGE SELLING PRICE OF SERVICES, BY KEY PLAYER
  • 5.5.3 AVERAGE SELLING PRICE TREND, BY REGION
• 5.6 TRADE ANALYSIS
  • 5.6.1 IMPORT SCENARIO (HS CODE 382200)
  • 5.6.2 EXPORT SCENARIO (HS CODE 382200)
  • 5.6.3 IMPORT SCENARIO (HS CODE 902700)
  • 5.6.4 EXPORT SCENARIO (HS CODE 902700)
• 5.7 KEY CONFERENCES & EVENTS, 2026-2027
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.9 INVESTMENT & FUNDING SCENARIO
• 5.10 CASE STUDY ANALYSIS
  • 5.10.1 COMPREHENSIVE GENOMIC PROFILING TEST EXPANDS PRECISION ONCOLOGY APPLICATIONS
  • 5.10.2 ULTRA-SENSITIVE NGS PANEL ENABLES MEASURABLE RESIDUAL DISEASE MONITORING
  • 5.10.3 NGS-BASED MYELOID FUSION PANEL ENHANCES HEMATOLOGIC MALIGNANCY RESEARCH
• 5.11 IMPACT OF 2025 US TARIFF ON NEXT-GENERATION SEQUENCING MARKET
  • 5.11.1 INTRODUCTION
  • 5.11.2 KEY TARIFF RATES
  • 5.11.3 PRICE IMPACT ANALYSIS
  • 5.11.4 IMPACT ON COUNTRY/REGION
    • 5.11.4.1 US
    • 5.11.4.2 Europe
    • 5.11.4.3 Asia Pacific
  • 5.11.5 IMPACT ON END-USE INDUSTRIES
    • 5.11.5.1 Pharmaceutical & biotechnology companies
    • 5.11.5.2 CROs and academic & research institutes
    • 5.11.5.3 Hospitals, diagnostic laboratories, and clinics

6 CUSTOMER LANDSCAPE & BUYER BEHAVIOUR

• 6.1 DECISION-MAKING PROCESS
• 6.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 6.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 6.2.2 KEY BUYING CRITERIA FOR NGS PRODUCTS, BY END USER
• 6.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 6.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
    • 7.1.2.1 North America
    • 7.1.2.2 Europe
    • 7.1.2.3 Asia Pacific
    • 7.1.2.4 Rest of the world
• 7.2 SUSTAINABILITY INITIATIVES
• 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
• 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 8.1 TECHNOLOGY ANALYSIS
  • 8.1.1 KEY TECHNOLOGIES
    • 8.1.1.1 Sequencing by synthesis
    • 8.1.1.2 Ion semiconductor sequencing
    • 8.1.1.3 Nanopore sequencing
    • 8.1.1.4 Single-molecule real-time sequencing (SMRT)
  • 8.1.2 COMPLEMENTARY TECHNOLOGIES
    • 8.1.2.1 Automated sample preparation systems
    • 8.1.2.2 Bioinformatics and data analysis platforms
    • 8.1.2.3 CRISPR-based targeted sequencing
    • 8.1.2.4 Multiplex PCR
  • 8.1.3 ADJACENT TECHNOLOGIES
    • 8.1.3.1 Single-cell sequencing technology
    • 8.1.3.2 Multiomics integration
    • 8.1.3.3 Spatial genomics and transcriptomics
    • 8.1.3.4 Gene editing technologies
• 8.2 TECHNOLOGY ROADMAP
• 8.3 PATENT ANALYSIS
  • 8.3.1 METHODOLOGY
  • 8.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
  • 8.3.3 LIST OF KEY PATENTS
• 8.4 FUTURE APPLICATIONS
• 8.5 IMPACT OF AI/GEN AI ON NEXT-GENERATION SEQUENCING MARKET
  • 8.5.1 TOP USE CASES AND MARKET POTENTIAL
  • 8.5.2 BEST PRACTICES IN AI-ENABLED NGS WORKFLOWS
  • 8.5.3 CASE STUDIES OF AI IMPLEMENTATION IN NEXT-GENERATION SEQUENCING MARKET
  • 8.5.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 8.5.5 CLIENTS' READINESS TO ADOPT AI-INTEGRATED SEQUENCING SOLUTIONS IN NEXT-GENERATION SEQUENCING MARKET

9 NEXT-GENERATION SEQUENCING MARKET, BY OFFERING

• 9.1 INTRODUCTION
• 9.2 PRODUCTS
  • 9.2.1 DEMAND FOR CONSUMABLES AND TECHNOLOGICAL ADVANCEMENTS TO PROPEL MARKET
• 9.3 SERVICES
  • 9.3.1 SHIFT TOWARD SERVICE-BASED MODELS TO DRIVE MARKET

10 NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY TYPE

• 10.1 INTRODUCTION
• 10.2 CONSUMABLES
  • 10.2.1 LIBRARY PREPARATION KITS & REAGENTS
    • 10.2.1.1 Strong demand and growing applications to ensure market growth
  • 10.2.2 SEQUENCING KITS & REAGENTS
    • 10.2.2.1 Focus on technological advancements to support market growth
  • 10.2.3 OTHER CONSUMABLES
• 10.3 PLATFORMS
  • 10.3.1 SEQUENCING PLATFORMS
    • 10.3.1.1 Need for advanced technologies to decode genetic information to drive market
    • 10.3.1.2 Illumina
      • 10.3.1.2.1 NovaSeq Series (X/X Plus)
        • 10.3.1.2.1.1 Next-generation ultra-high throughput sequencing to enable large-scale genomics
      • 10.3.1.2.2 MiSeq/MiSeq i100
        • 10.3.1.2.2.1 Compact sequencing platforms to enable rapid and targeted genomic analysis
      • 10.3.1.2.3 NextSeq 1k/2K and 550
        • 10.3.1.2.3.1 Mid-throughput sequencing systems to support diverse research and clinical applications
      • 10.3.1.2.4 NovaSeq 6000
        • 10.3.1.2.4.1 High-throughput sequencing platform to enable large-scale genomic studies
    • 10.3.1.3 Thermo Fisher Scientific
    • 10.3.1.4 PacBio
      • 10.3.1.4.1 Revio
        • 10.3.1.4.1.1 High-throughput long-read sequencing to support market growth
      • 10.3.1.4.2 Sequel II/IIe
        • 10.3.1.4.2.1 High-accuracy, long-read sequencing to support market growth
      • 10.3.1.4.3 Vega Seq
        • 10.3.1.4.3.1 Benchtop long-read sequencing platform to support market growth
    • 10.3.1.5 Oxford Nanopore Technologies
    • 10.3.1.6 Other sequencing platforms
  • 10.3.2 LIBRARY PREPARATION PLATFORMS
    • 10.3.2.1 Rising demand for sequencing in clinical applications to drive market
• 10.4 BIOINFORMATICS TOOLS
  • 10.4.1 DATA ANALYSIS SOFTWARE & WORKBENCHES
    • 10.4.1.1 Demand for genome analysis in clinical diagnostics to support market growth
  • 10.4.2 DATA VISUALIZATION TOOLS
    • 10.4.2.1 Rising demand for sequencing-based research to support market growth
  • 10.4.3 OTHER BIOINFORMATICS TOOLS

11 NEXT-GENERATION SEQUENCING PLATFORMS MARKET, BY TECHNOLOGY

• 11.1 INTRODUCTION
• 11.2 SEQUENCING BY SYNTHESIS
  • 11.2.1 HIGH, RAPID PRODUCTION OF BASE PAIRS TO SUPPORT ADOPTION
• 11.3 ION SEMICONDUCTOR SEQUENCING
  • 11.3.1 SIMPLER WORKFLOW AND COST-EFFECTIVENESS TO SUPPORT MARKET GROWTH
• 11.4 SMRT SEQUENCING
  • 11.4.1 FOCUS ON RAPID RESULTS AND LOWER SEQUENCING COSTS TO DRIVE MARKET
• 11.5 NANOPORE SEQUENCING
  • 11.5.1 EMPHASIS ON DIRECT RNA SEQUENCING CAPABILITIES TO PROPEL DEMAND
• 11.6 OTHER SEQUENCING TECHNOLOGIES

12 NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY WORKFLOW

• 12.1 INTRODUCTION
• 12.2 SEQUENCING
  • 12.2.1 ABILITY TO ADDRESS COMPLEX GENOMIC REGIONS AND RESOLVE STRUCTURAL VARIATIONS TO DRIVE MARKET
• 12.3 PRESEQUENCING
  • 12.3.1 INCREASED RESEARCH AND SUPPLY AGREEMENTS BETWEEN INDUSTRY PARTICIPANTS TO DRIVE MARKET
• 12.4 DATA ANALYSIS
  • 12.4.1 RISE OF IN-HOUSE INSTALLATION OF BIOINFORMATICS INFRASTRUCTURE TO DRIVE MARKET

13 NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 ACADEMIC & RESEARCH INSTITUTES
  • 13.2.1 RISING RESEARCH INTENSITY FOR GENOME RESEARCH AMONG INSTITUTES TO SUPPORT MARKET GROWTH
• 13.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 13.3.1 RISING DEMAND FOR COMPREHENSIVE SEQUENCING DATA IN GENETIC RESEARCH TO DRIVE MARKET
• 13.4 CLINICAL & DIAGNOSTIC LABORATORIES
  • 13.4.1 INCREASED APPLICATIONS IN DISEASE DIAGNOSTICS AND TREATMENT TO DRIVE MARKET GROWTH
• 13.5 OTHER END USERS

14 NEXT-GENERATION SEQUENCING SERVICES MARKET, BY TYPE

• 14.1 INTRODUCTION
• 14.2 SEQUENCING SERVICES
  • 14.2.1 EXOME & TARGETED RESEQUENCING SERVICES AND CUSTOM PANELS
    • 14.2.1.1 Advancements in target enrichment technologies to drive market
  • 14.2.2 RNA SEQUENCING SERVICES
    • 14.2.2.1 Launch of RNA services and availability of diverse RNA bioinformatics tools to drive market
  • 14.2.3 DE NOVO SEQUENCING SERVICES
    • 14.2.3.1 Need for more accurate and faster characterization than traditional methods to drive market
  • 14.2.4 CHIP SEQUENCING SERVICES
    • 14.2.4.1 Surge in demand from academic and research institutes to drive market
  • 14.2.5 WHOLE-GENOME SEQUENCING SERVICES
    • 14.2.5.1 Technological advancements in next-generation sequencing products to drive market
  • 14.2.6 METHYL SEQUENCING SERVICES
    • 14.2.6.1 Large-scale adoption in cancer research to drive market
  • 14.2.7 OTHER SEQUENCING SERVICES
• 14.3 PRESEQUENCING SERVICES
  • 14.3.1 LIBRARY PREPARATION & TARGET ENRICHMENT SERVICES
    • 14.3.1.1 Development of advanced library preparation solutions to drive market
  • 14.3.2 SAMPLE PREPARATION SERVICES
    • 14.3.2.1 Applicability in oncology, infectious diseases, metagenomics, and epigenetics to drive market
  • 14.3.3 QUALITY CONTROL SERVICES
    • 14.3.3.1 Growing research activities using next-generation sequencing technology to drive market
• 14.4 BIOINFORMATICS & DATA ANALYSIS SERVICES
  • 14.4.1 DATA ANALYSIS SERVICES
    • 14.4.1.1 Increasing demand for precision and speed in genomics for clinical diagnosis to drive market
  • 14.4.2 DATA VISUALIZATION & INTERPRETATION SERVICES
    • 14.4.2.1 Rising demand for sequencing-based research to drive market
  • 14.4.3 DATA STORAGE & MANAGEMENT SERVICES
    • 14.4.3.1 Need for effective data management to drive market
• 14.5 NGS PLATFORM SERVICES
  • 14.5.1 COMPLIANCE WITH STRINGENT QUALITY AND OPERATIONAL REQUIREMENTS TO DRIVE MARKET

15 NEXT-GENERATION SEQUENCING SERVICES MARKET, BY WORKFLOW

• 15.1 INTRODUCTION
• 15.2 SEQUENCING
  • 15.2.1 RISING DEMAND FOR SEQUENCING SERVICES AND APPLICATIONS IN CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH
• 15.3 PRESEQUENCING SERVICES
  • 15.3.1 CUSTOM DEVELOPMENT OF SAMPLES FOR SEQUENCING TO BOOST MARKET GROWTH
• 15.4 DATA ANALYSIS SERVICES
  • 15.4.1 RISING DEMAND FOR ADVANCED RESEARCH TO DRIVE MARKET

16 NEXT-GENERATION SEQUENCING SERVICES MARKET, BY END USER

• 16.1 INTRODUCTION
• 16.2 ACADEMIC & RESEARCH INSTITUTES
  • 16.2.1 GROWING RESEARCH INTENSITY TO SUPPORT MARKET GROWTH
• 16.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 16.3.1 RISING DEMAND FOR COMPREHENSIVE GENETIC DATA TO DRIVE GROWTH
• 16.4 HOSPITALS & CLINICAL LABORATORIES
  • 16.4.1 INCREASED APPLICATION IN NGS IN DISEASE DIAGNOSTICS AND TREATMENT TO DRIVE GROWTH
• 16.5 OTHER END USERS

17 NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION

• 17.1 INTRODUCTION
• 17.2 DIAGNOSTICS
  • 17.2.1 CANCER DIAGNOSTICS
    • 17.2.1.1 Rising demand for targeted therapies to drive market
  • 17.2.2 INFECTIOUS DISEASE DIAGNOSTICS
    • 17.2.2.1 Rising demand for comprehensive genomic data in clinical diagnostics to propel growth
  • 17.2.3 REPRODUCTIVE HEALTH DIAGNOSTICS
    • 17.2.3.1 Focus on genetic disease diagnostics to drive growth
  • 17.2.4 OTHER DIAGNOSTIC APPLICATIONS
• 17.3 DRUG DISCOVERY & DEVELOPMENT
  • 17.3.1 PHARMACOGENOMICS
    • 17.3.1.1 Rising use of NGS for understanding genomic variants in humans to drive growth
  • 17.3.2 OTHER DRUG DISCOVERY & DEVELOPMENT APPLICATIONS
• 17.4 AGRICULTURE & ANIMAL RESEARCH
  • 17.4.1 EMPHASIS ON IMPROVING CROP PRODUCTIVITY TO DRIVE ADOPTION OF NGS
• 17.5 OTHER APPLICATIONS

18 NEXT-GENERATION SEQUENCING MARKET, BY REGION

• 18.1 INTRODUCTION
• 18.2 NORTH AMERICA
  • 18.2.1 US
    • 18.2.1.1 Rapid growth and advancements to lead market
  • 18.2.2 CANADA
    • 18.2.2.1 Increasing government initiatives in sequencing research to boost market growth
• 18.3 EUROPE
  • 18.3.1 GERMANY
    • 18.3.1.1 Adoption of advanced sequencing technologies to drive market
  • 18.3.2 UK
    • 18.3.2.1 Strategic initiatives and funding for genomics research to support market growth
  • 18.3.3 FRANCE
    • 18.3.3.1 Increasing government investment in genomics research to drive growth
  • 18.3.4 ITALY
    • 18.3.4.1 Favorable funding scenario to drive adoption of advanced sequencing technology
  • 18.3.5 SPAIN
    • 18.3.5.1 Growing focus on advancements in personalized medicine to support market growth
  • 18.3.6 NETHERLANDS
    • 18.3.6.1 Well-established research infrastructure to sustain demand for NGS
  • 18.3.7 REST OF EUROPE
• 18.4 ASIA PACIFIC
  • 18.4.1 CHINA
    • 18.4.1.1 Favorable regulatory reforms to drive market
  • 18.4.2 JAPAN
    • 18.4.2.1 Rising number of collaborations in NGS to drive market
  • 18.4.3 INDIA
    • 18.4.3.1 Government and private initiatives for genomics projects to propel market
  • 18.4.4 AUSTRALIA
    • 18.4.4.1 Increased genetic research in Australia to support market growth
  • 18.4.5 SOUTH KOREA
    • 18.4.5.1 Demand for advanced sequencing technologies to support market
  • 18.4.6 REST OF ASIA PACIFIC
• 18.5 LATIN AMERICA
  • 18.5.1 BRAZIL
    • 18.5.1.1 Increased government investments in genomics advancements to drive market
  • 18.5.2 MEXICO
    • 18.5.2.1 Rising demand for chronic disease treatment to support growth
  • 18.5.3 REST OF LATIN AMERICA
• 18.6 MIDDLE EAST
  • 18.6.1 GCC COUNTRIES
    • 18.6.1.1 Saudi Arabia
      • 18.6.1.1.1 Growing healthcare expenditure in Saudi Arabia to boost market growth
    • 18.6.1.2 UAE
      • 18.6.1.2.1 Collaborations to advance genome sequencing and market growth
    • 18.6.1.3 Rest of GCC countries
  • 18.6.2 REST OF MIDDLE EAST
• 18.7 AFRICA
  • 18.7.1 GROWING FOCUS ON PRECISION MEDICINE TO PROPEL MARKET

19 COMPETITIVE LANDSCAPE

• 19.1 INTRODUCTION
• 19.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 19.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NGS MARKET
• 19.3 REVENUE ANALYSIS, 2021-2025
• 19.4 MARKET SHARE ANALYSIS, 2025
• 19.5 BRAND/PRODUCT COMPARISON
• 19.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 19.6.1 STARS
  • 19.6.2 EMERGING LEADERS
  • 19.6.3 PERVASIVE PLAYERS
  • 19.6.4 PARTICIPANTS
  • 19.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 19.6.5.1 Company footprint
    • 19.6.5.2 Region footprint
    • 19.6.5.3 Offering footprint
    • 19.6.5.4 Application footprint
    • 19.6.5.5 Technology footprint
• 19.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 19.7.1 PROGRESSIVE COMPANIES
  • 19.7.2 RESPONSIVE COMPANIES
  • 19.7.3 DYNAMIC COMPANIES
  • 19.7.4 STARTING BLOCKS
  • 19.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 19.7.5.1 Detailed list of key startups/SMEs
    • 19.7.5.2 Competitive benchmarking of startups/SMEs
• 19.8 COMPANY VALUATION & FINANCIAL METRICS
  • 19.8.1 COMPANY VALUATION
  • 19.8.2 FINANCIAL METRICS
• 19.9 COMPETITIVE SCENARIO
  • 19.9.1 PRODUCT LAUNCHES
  • 19.9.2 DEALS
  • 19.9.3 EXPANSIONS

20 COMPANY PROFILES

• 20.1 KEY PLAYERS
  • 20.1.1 ILLUMINA, INC.
    • 20.1.1.1 Business overview
    • 20.1.1.2 Products/Services offered
    • 20.1.1.3 Recent developments
      • 20.1.1.3.1 Product launches
      • 20.1.1.3.2 Deals
    • 20.1.1.4 MnM view
      • 20.1.1.4.1 Key strengths
      • 20.1.1.4.2 Strategic choices
      • 20.1.1.4.3 Weaknesses and competitive threats
  • 20.1.2 THERMO FISHER SCIENTIFIC INC.
    • 20.1.2.1 Business overview
    • 20.1.2.2 Products/Services offered
    • 20.1.2.3 Recent developments
      • 20.1.2.3.1 Product launches
      • 20.1.2.3.2 Deals
      • 20.1.2.3.3 Expansions
    • 20.1.2.4 MnM view
      • 20.1.2.4.1 Key strengths
      • 20.1.2.4.2 Strategic choices
      • 20.1.2.4.3 Weaknesses and competitive threats
  • 20.1.3 AGILENT TECHNOLOGIES, INC.
    • 20.1.3.1 Business overview
    • 20.1.3.2 Products/Services offered
    • 20.1.3.3 Recent developments
      • 20.1.3.3.1 Deals
      • 20.1.3.3.2 Expansions
    • 20.1.3.4 MnM view
      • 20.1.3.4.1 Key strengths
      • 20.1.3.4.2 Strategic choices
      • 20.1.3.4.3 Weaknesses and competitive threats
  • 20.1.4 F. HOFFMANN-LA ROCHE LTD.
    • 20.1.4.1 Business overview
    • 20.1.4.2 Products/Services offered
    • 20.1.4.3 Recent developments
      • 20.1.4.3.1 Product launches
      • 20.1.4.3.2 Deals
      • 20.1.4.3.3 Other developments
    • 20.1.4.4 MnM view
      • 20.1.4.4.1 Key strengths
      • 20.1.4.4.2 Strategic choices
      • 20.1.4.4.3 Weaknesses and competitive threats
  • 20.1.5 QIAGEN
    • 20.1.5.1 Business overview
    • 20.1.5.2 Products/services offered
    • 20.1.5.3 Recent developments
      • 20.1.5.3.1 Deals
      • 20.1.5.3.2 Expansions
    • 20.1.5.4 MnM view
      • 20.1.5.4.1 Key strengths
      • 20.1.5.4.2 Strategic choices
      • 20.1.5.4.3 Weaknesses and competitive threats
  • 20.1.6 DANAHER CORPORATION
    • 20.1.6.1 Business overview
    • 20.1.6.2 Products/services offered
    • 20.1.6.3 Recent developments
      • 20.1.6.3.1 Product launches
      • 20.1.6.3.2 Deals
      • 20.1.6.3.3 Expansions
  • 20.1.7 REVVITY
    • 20.1.7.1 Business overview
    • 20.1.7.2 Products/Services offered
    • 20.1.7.3 Recent developments
      • 20.1.7.3.1 Product launches
      • 20.1.7.3.2 Deals
      • 20.1.7.3.3 Expansions
  • 20.1.8 EUROFINS SCIENTIFIC
    • 20.1.8.1 Business overview
    • 20.1.8.2 Products/services offered
    • 20.1.8.3 Recent developments
      • 20.1.8.3.1 Deals
  • 20.1.9 PACBIO
    • 20.1.9.1 Business overview
    • 20.1.9.2 Products/Services offered
    • 20.1.9.3 Recent developments
      • 20.1.9.3.1 Product launches
      • 20.1.9.3.2 Deals
      • 20.1.9.3.3 Expansions
  • 20.1.10 OXFORD NANOPORE TECHNOLOGIES PLC
    • 20.1.10.1 Business overview
    • 20.1.10.2 Products/Services offered
    • 20.1.10.3 Recent developments
      • 20.1.10.3.1 Deals
      • 20.1.10.3.2 Expansions
  • 20.1.11 TAKARA BIO INC.
    • 20.1.11.1 Business overview
    • 20.1.11.2 Products/Services offered
    • 20.1.11.3 Recent developments
      • 20.1.11.3.1 Deals
  • 20.1.12 BGI GROUP
    • 20.1.12.1 Business overview
    • 20.1.12.2 Products/Services offered
  • 20.1.13 BD
    • 20.1.13.1 Business overview
    • 20.1.13.2 Products/Services offered
    • 20.1.13.3 Recent developments
      • 20.1.13.3.1 Product launches
  • 20.1.14 10X GENOMICS
    • 20.1.14.1 Business overview
    • 20.1.14.2 Products/Services offered
  • 20.1.15 PROMEGA CORPORATION
    • 20.1.15.1 Business overview
    • 20.1.15.2 Products/Services offered
  • 20.1.16 LGC LIMITED
    • 20.1.16.1 Business overview
    • 20.1.16.2 Products/Services offered
    • 20.1.16.3 Recent developments
      • 20.1.16.3.1 Deals
  • 20.1.17 WUXI BIOLOGICS
    • 20.1.17.1 Business overview
    • 20.1.17.2 Products/Services offered
  • 20.1.18 TECAN TRADING AG
    • 20.1.18.1 Business overview
    • 20.1.18.2 Products/Services offered
    • 20.1.18.3 Recent developments
      • 20.1.18.3.1 Deals
  • 20.1.19 TWIST BIOSCIENCE
    • 20.1.19.1 Business overview
    • 20.1.19.2 Products/Services offered
    • 20.1.19.3 Recent developments
      • 20.1.19.3.1 Product launches
      • 20.1.19.3.2 Deals
  • 20.1.20 AZENTA US INC.
    • 20.1.20.1 Business overview
    • 20.1.20.2 Products/Services offered
    • 20.1.20.3 Recent developments
      • 20.1.20.3.1 Deals
• 20.2 OTHER PLAYERS
  • 20.2.1 MGI TECH CO. LTD.
  • 20.2.2 NOVOGENE CO., LTD.
  • 20.2.3 NEW ENGLAND BIOLABS
  • 20.2.4 GENSCRIPT
  • 20.2.5 PSOMAGEN
  • 20.2.6 ZYMO RESEARCH CORPORATION
  • 20.2.7 HAMILTON COMPANY
  • 20.2.8 NEOGENOMICS LABORATORIES
  • 20.2.9 FULGENT GENETICS
  • 20.2.10 SD BIOSENSOR, INC.

21 RESEARCH METHODOLOGY

• 21.1 RESEARCH DATA
  • 21.1.1 SECONDARY DATA
    • 21.1.1.1 Key data from secondary sources
  • 21.1.2 PRIMARY DATA
    • 21.1.2.1 Key data from primary sources
    • 21.1.2.2 Key primary participants
    • 21.1.2.3 Breakdown of primary interviews
    • 21.1.2.4 Key industry insights
• 21.2 MARKET SIZE ESTIMATION
  • 21.2.1 GLOBAL NEXT-GENERATION SEQUENCING MARKET ESTIMATION, 2025
  • 21.2.2 SEGMENTAL MARKET SIZE ESTIMATION
• 21.3 MARKET GROWTH RATE PROJECTIONS
• 21.4 DATA TRIANGULATION
• 21.5 FACTOR ANALYSIS
• 21.6 RESEARCH ASSUMPTIONS
• 21.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT

22 APPENDIX

• 22.1 DISCUSSION GUIDE
• 22.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 22.3 CUSTOMIZATION OPTIONS
• 22.4 RELATED REPORTS
• 22.5 AUTHOR DETAILS